NRSNW
Price:
$0.15
Market Cap:
$17.52M
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
NRSNW
According to NeuroSense Therapeutics Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 16.35M. This represents a change of 8.41% compared to the average of 15.08M of the last 4 quarters.
The mean historical Enterprise Value of NeuroSense Therapeutics Ltd. over the last ten years is 5.70M. The current 16.35M Enterprise Value has changed 28.59% with respect to the historical average. Over the past ten years (40 quarters), NRSNW's Enterprise Value was at its highest in in the March 2021 quarter at 44.91M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.
Average
5.70M
Median
7.14M
Minimum
-4460203.96
Maximum
10.70M
Discovering the peaks and valleys of NeuroSense Therapeutics Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.82%
Maximum Annual Enterprise Value = 10.70M
Minimum Annual Increase = -339.98%
Minimum Annual Enterprise Value = -4460203.96
Year | Enterprise Value | Change |
---|---|---|
2023 | 8.17M | -23.68% |
2022 | 10.70M | -339.98% |
2021 | -4460203.96 | -162.45% |
2020 | 7.14M | 2.82% |
The current Enterprise Value of NeuroSense Therapeutics Ltd. (NRSNW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
4.80M
5-year avg
5.70M
10-year avg
5.70M
NeuroSense Therapeutics Ltd.’s Enterprise Value is less than NeuroSense Therapeutics Ltd. (16.35M), greater than Pasithea Therapeutics Corp. (-5435245.00), less than GeoVax Labs, Inc. (19.24M), greater than NLS Pharmaceutics AG (9.64M), greater than Cingulate Inc. (5.36M),
Company | Enterprise Value | Market cap |
---|---|---|
16.35M | $17.52M | |
-5435245.00 | $4.04M | |
19.24M | $21.97M | |
9.64M | $8.19M | |
5.36M | $15.42M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeuroSense Therapeutics Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NeuroSense Therapeutics Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is NeuroSense Therapeutics Ltd.'s Enterprise Value?
What is the highest Enterprise Value for NeuroSense Therapeutics Ltd. (NRSNW)?
What is the 3-year average Enterprise Value for NeuroSense Therapeutics Ltd. (NRSNW)?
What is the 5-year average Enterprise Value for NeuroSense Therapeutics Ltd. (NRSNW)?
How does the current Enterprise Value for NeuroSense Therapeutics Ltd. (NRSNW) compare to its historical average?